426 / 1631
•
HL highly curable; long-term toxicity
•
Early stages: 2-4xABVD+RT; „2+2“+RT PET driven
•
Advanced stages: B.esc vs ABVD (15-20% better PFS and 10-
15% OS vs more hematotox and infertility)
•
Only 4xB.esc needed in PET- pts (3y FFTF 94.8%; OS 98.7%)
•
ECHELON-1: BV-AVD vs ABVD; mPFS@2yrs 4.9%
•
PD1 inhibition such as Nivo-AVD being evaluated in 1st line
•
Future trials including anti-PD1 Moabs will increasingly
replace chemo- and radiotherapy in HL
Advanced and relapsed Hodgkin Lymphoma 2018